NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq technologies. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
IPO Year: 2013
Exchange: NASDAQ
Website: nanostring.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/27/2023 | Overweight → Neutral | JP Morgan | |
| 11/21/2023 | Outperform → Neutral | Robert W. Baird | |
| 7/5/2023 | $18.00 | Overweight | JP Morgan |
| 2/2/2023 | $15.00 | Buy | UBS |
| 3/24/2022 | $50.00 | Buy | Canaccord Genuity |
| 3/2/2022 | $85.00 → $70.00 | Overweight | JP Morgan |
$47.5 Million in New Financing Secured from Existing Noteholders, Upsized from Initial $40 million Commitment Supports Mission to Continue Serving Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the Company has entered into a credit agreement with its existing lenders comprised of (a) $12,500,000 in new money term loans which have already been approved for funding pursuant to the February 5 interim order of the U.S. Bankruptcy court approving the credit facility, and (b) an additional $35,000,000 in new money term loans to be funded upon entry of the final
Initiates Voluntary Chapter 11 Restructuring Proceedings with Additional $40 Million in Financing Secured from Existing Noteholders to Facilitate Process Continuing to Serve Life Sciences Researchers Worldwide NanoString Technologies, Inc. (NASDAQ:NSTG) ("NanoString" or "the Company"), a leading provider of life science tools for discovery and translational research, today announced that steps are being taken to protect its business, customers, employees and its mission to "Map the Universe of Biology." With support from key creditors, NanoString and certain of its subsidiaries have voluntarily initiated a chapter 11 restructuring proceeding in the United States Bankruptcy Court for the
Three customers will present inaugural studies powered by the novel CosMx Whole Transcriptome Panel during annual AGBT meeting NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K Discovery Panel, the industry's first single-cell spatial panel enabling research scientists to measure over 6,000 RNA targets, representing nearly every human biological pathway. Building on this breakthrough product developed for the CosMx Spatial Molecular Imager (SMI), NanoString and independent researchers will also highlight recently achieved whole transcriptome imag
Major milestone marked by first public dataset released for CosMx Whole Transcriptome Panel with additional data forthcoming at the AGBT Meeting NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the release of the first public dataset of the whole transcriptome obtained at true single-cell resolution on the CosMx™ Spatial Molecular Imager (SMI). The data will be highlighted at the 42nd annual J.P. Morgan Healthcare Conference 2024 in San Francisco during NanoString's corporate presentation on Wednesday, January 10, 2024, at 5:15 pm ET. CosMx Whole Transcriptome Panel Achieves Scientific Moonsho
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity inducement awards to 10 new employees. In accordance with Nasdaq Listing Rule 5635(c)(4), on December 6, 2023, the Compensation and Human Capital Committee of NanoString's Board of Directors approved the grant of, in the aggregate, 34,925 restricted stock units, or RSUs, as material inducements to the 10 employees entering into employment with NanoString. One-third of the RSUs vest on the first market trading day on or following the first anniversary of the grant date and one-third of the RSUs vest
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a presentation from the 42nd annual J.P. Morgan healthcare conference, being held January 8-11, 2024. Brad Gray, president and chief executive officer, is scheduled to present on Wednesday, January 10, at 5:15pm ET. Interested parties can access the live webcast from the investor section of the company's website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 30 days. About NanoString NanoString Technologies, a le
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, commented on the November 17th verdict of a jury in the U.S. District Court for the District of Delaware finding that NanoString GeoMx® Digital Spatial Profiler products infringe patents licensed to 10x Genomics and awarding approximately $31 million in damages, consisting of approximately $25 million of lost profits and a $6 million royalty. "We respectfully disagree with the jury's verdict, which we will seek to have overturned or amended in our post-trial motions and then expect to appeal to the U.S. Court of Appeals for the Federal Circuit, a court that speci
Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies, Inc. (NASDAQ:NSTG). In awarding over $31 million in damages, the jury found that NanoString's GeoMx
Twenty-two posters and two symposia to be offered at Neuroscience 2023 NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms. NanoString will offer attendees the first look at a proof-of-concept study featuring its new CosMx™ Mouse Universal Cell Characterization RNA panel plus its 64-plex CosMx Mouse Neuroscience Protein panel from the same slide. The presentation will be delivered by Caleb Stokes, M.D., Ph.D. of the University
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast presentations from two upcoming healthcare conferences. Stifel 2023 Healthcare Conference Tuesday, November 14th Tom Bailey, NanoString's chief financial officer, and Doug Farrell, VP of Investor Relations, will participate in a fireside discussion hosted by Stifel analyst Dan Arias at 9:45am ET. Jefferies London Healthcare Conference Thursday, November 16th Tom Bailey, NanoString's chief financial officer, will provide a corporate update at the Jefferies conference at 2:30pm GMT. Interested part
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
3 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
4 - NanoString Technologies Inc (0001401708) (Issuer)
JP Morgan downgraded NanoString Technologies from Overweight to Neutral
Robert W. Baird downgraded NanoString Technologies from Outperform to Neutral
JP Morgan resumed coverage of NanoString Technologies with a rating of Overweight and set a new price target of $18.00
UBS initiated coverage of NanoString Technologies with a rating of Buy and set a new price target of $15.00
Canaccord Genuity initiated coverage of NanoString Technologies with a rating of Buy and set a new price target of $50.00
JP Morgan reiterated coverage of NanoString Technologies with a rating of Overweight and set a new price target of $70.00 from $85.00 previously
Morgan Stanley reiterated coverage of NanoString Technologies with a rating of Equal-Weight and set a new price target of $65.00 from $70.00 previously
Morgan Stanley reiterated coverage of NanoString Technologies with a rating of Equal Weight and set a new price target of $70.00 from $55.00 previously
Morgan Stanley reiterated coverage of NanoString Technologies with a rating of Equal-Weight and set a new price target of $70.00 from $55.00 previously
JPMorgan Chase & Co. reiterated coverage of NanoString Technologies with a rating of Overweight and set a new price target of $80.00 from $75.00 previously
8-K - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
EFFECT - NanoString Technologies Inc (0001401708) (Filer)
424B3 - NanoString Technologies Inc (0001401708) (Filer)
S-3 - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
8-K - NanoString Technologies Inc (0001401708) (Filer)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G - NanoString Technologies Inc (0001401708) (Subject)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G - NanoString Technologies Inc (0001401708) (Subject)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13G/A - NanoString Technologies Inc (0001401708) (Subject)
SC 13D/A - NanoString Technologies Inc (0001401708) (Subject)
NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for discovery and translational research, today announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230826560279/en/NanoString Appoints Todd Garland as Chief Commercial Officer (Photo: Business Wire) Mr. Garland is a senior executive with more than 25 years of experience in healthcare and life sciences technologies that serve customers in the discovery, translational and clinical markets. Most recently Mr. Garland served as Chief Commercial Officer at Cytek B
DermTech, Inc. (NASDAQ:DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company's board of directors, effective July 18,2022. These appointments expand DermTech's board of directors to eight members. "We are excited to welcome Kirk and Mark as new independent directors," commented Matt Posard, DermTech's chairman. "They are both accomplished life science executives, with an established track record in building companies, business development, capital formation and strategic partnerships. Their perspectives in guiding high-growth co
Dr. Rob Hershberg steps down from Board after seven years of service NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of Dr. Teresa (Teri) Foy to the Board of Directors, effective April 18, 2022. "I am honored to welcome Dr. Foy to the team. Teri is a leader in immuno-oncology and cellular therapy, with decades of experience in pharmaceutical research," said president and chief executive officer Brad Gray. "Immunology and oncology are two of the most important applications for spatial biology, and Teri brings a wealth of knowledge in the ways that life science tools are utilized
Chad Brown to Retire Following More than Four Successful Years as SVP, Sales & Marketing Genomics and Diagnostics Veteran John D. Gerace Appointed as Chief Commercial Officer NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced a commercial leadership transition. Chad Brown, who has served as senior vice president of Sales & Marketing since June 2017, will be shifting into a part-time senior advisor role effective April 1, before fully retiring in March 2023. John D. Gerace has been named to the position of Chief Commercial Officer effective immediately. Mr. Brown joined NanoString in July 2017 and
Innovator in single-cell spatial transcriptomics expands its commercial team, turning an eye towards the global market Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has announced the appointment of Dale Levitzke as Senior Vice President Global Sales and Support. The expansion of Vizgen's commercial team will support the escalating demand for its MERSCOPE Platform ahead of the full US launch at the end of 2021. In his role, Dale will be responsible for guiding the company towards a global MERSCOPE product launch in 2022, in part by growing distribution channels to match the massive market demand for spatial geno
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the first quarter ended March 31, 2021. First Quarter Financial Highlights Product and service revenue of $31.4 million, 28% year-over-year growth Instrument revenue of $11.7 million, 19% year-over-year growth. Instrument revenue includes $7.0 million of GeoMx® Digital Spatial Profiler (DSP) instrument revenue Consumables revenue of $16.0 million, 39% year-over-year growth. Consumables revenue includes $2.7 million GeoMx® DSP consumables revenue Service revenue of $3.7 million, 17% year-over-year growth Cash, cash equ
SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the appointment of two new board members, Dr. Dana Rollison and Janet George, effective March 8, 2021. "I'm thrilled to welcome Dana and Janet to the team. Our new board members bring valuable expertise, skills and strategic vision to NanoString," said president and chief executive officer, Brad Gray. "Their appointments reflect the unique informatics and big data opportunities that are inherent in spatial biology, and the depth and breadth of their experience will be instrumental in guiding our leadership team
Completed Exchange Transaction with Convertible Note Holders Representing 94% of Outstanding Principal – Record Q3 Revenue of $48.1 Million, 63% Year on Year Growth and Above Upper End of Q3 Guidance Range – NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2023. The Company also announced it had reached agreement with holders to exchange approximately $216 million, or 94%, principal amount of its Convertible Notes for new Senior Secured Notes due September 1, 2026 and common stock warrants. "The last few months have been extraordinar
- Record Q3 Revenue of Over $48 Million, 63% Year on Year Growth, Above Upper End of Q3 Guidance Range - - Implementing Reorganization of R&D and Manufacturing Operations to Improve Path to Profitability - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the third quarter ended September 30, 2023, as well as a reorganization designed to accelerate the Company's path to profitability. "Our teams delivered strong revenue results for the third quarter, with preliminary results exceeding consensus estimates and the high end of our guidance rang
– Record Q2 Revenue of $44.2 Million, 37% Year on Year Growth and Above Upper End of Q2 Guidance Range – - Retained More than $35 Million in CosMx Instrument Order Backlog at the End of Q2 - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter ended June 30, 2023. "Strong growth in our spatial biology business and continued durability in our nCounter business helped us generate record revenue during the second quarter," said Brad Gray, President and CEO of NanoString. "We expect to continue to benefit from substantial CosMx instrument order backlog through
- Record Q2 Revenue of Over $44 Million, 37% Year on Year Growth and Above Upper End of Q2 Guidance Range - - New Orders for CosMx Instruments Grew Sequentially and Year on Year - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for the second quarter ended June 30, 2023. "We are excited to report that our teams delivered strong preliminary revenue results for the second quarter, with preliminary results exceeding consensus estimates and the upper end of our guidance ranges," said Brad Gray, President and CEO of NanoString. "Customers are focus
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will host a conference call on Monday, May 22, 2023, at 4:30pm ET to provide an update on the recent Decision of the Regional Court of Munich. Investors and other interested parties should register for the conference call in advance by visiting https://www.netroadshow.com/events/login?show=9b96aaa1&confId=51426. Following registration, an email confirmation will be sent that includes dial-in details and unique conference call codes for entry. Registration is open throughout the call but to ensure connection for the full call, regi
– Q1 Revenue of $35.8 Million – – Total Spatial Biology and nCounter Revenue Above Upper End of Q1 Guidance Ranges – – Raising Annual Revenue Guidance to $175-185 Million – NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the first quarter ended March 31, 2023. "2023 is off to a strong start, with spatial biology revenue up more than 75% over the prior year," said Brad Gray, President and CEO of NanoString. "Demand for our CosMx Spatial Molecular Imager is robust, with new orders driving an increase in CosMx backlog even as we accelerated shipments in the first quarter
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report first quarter 2023 operating results after the close of the market on Wednesday, May 3, 2023. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update. Investors and other interested parties should register for the conference call in advance by visiting https://events.q4inc.com/attendee/850976054. Following registration, an email confirmation will be sent that includes dial-in details and unique conference call codes for entry. Registration is open thr
- Generated Record Orders for Over 105 Spatial Biology Instruments, Representing 50% Growth Year-over-Year - - Q4 Revenue Over $34 Million - NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022. "We are thrilled with the momentum that's building in the spatial biology market. In 2022, we grew spatial biology instrument orders 50% year-on-year, and with approximately $40 million of CosMx orders in backlog, we are well-positioned for strong revenue growth in 2023," said Brad Gray, President and CEO of NanoString. "At the
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report fourth quarter and fiscal year 2022 operating results after the close of the market on Tuesday, February 28, 2023. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update. Investors and other interested parties should register for the conference call in advance by visiting https://events.q4inc.com/attendee/430840159. Following registration, an email confirmation will be sent that includes dial-in details and unique conference call codes for entry. Regi
Generated Orders for ~60 Spatial Biology Instruments, Representing ~70% Growth Year-over-Year, Including Orders for ~40 CosMx Spatial Molecular Imagers NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the third quarter ended September 30, 2022. Third Quarter Financial Highlights Product and service revenue of $29.5 million GeoMx® Digital Spatial Profiler (DSP) revenue of $9.3 million. GeoMx DSP revenue includes: Instrument revenue of $4.7 million Consumables revenue of $4.6 million, annualized pull-through of approximately $58,000 per installed system nCounter® r